PBYI Puma Biotechnology Inc - Common Stock
NASDAQ · Biotechnology · Ver em SEC EDGAR ↗ fechar Out 2, 2026 10-K/10-Q Ago 6, 2026
$9,51
· % da faixa de 52 semanas
· acima do mínimo
· para alta
$4,58mínima 52 sem
$10,10máxima 52 sem
Capitalização de Mercado (MRQ)
$486M
P/E (TTM)
18.3
EPS (TTM)
$0.52
Receita (TTM)
$231M
seus distintivos
Intervalo 52 Semanas
$5–$10
Classificação do Analista
HOLD
Preço-Alvo
$6
P/E
18.3
ROE
22.0%
Margem de Lucro Líquido
11.6%
Sua barra de distintivos está vazia — fixe uma métrica em qualquer lugar desta página.
PBYI Instantâneo da Ação Preço, capitalização de mercado, P/E, EPS, ROE, dívida/patrimônio, intervalo de 52 semanas
Preço
$9.51
Capitalização de Mercado (MRQ)
$486M
P/E (TTM)
18.3
EPS (TTM)
$0.52
Receita (TTM)
$231M
ROE (TTM)
22.0%
Dívida/Capital (MRQ)
0.0
Intervalo 52 Semanas
$5–$10
PBYI Gráfico de Preço da Ação OHLCV diário com indicadores técnicos — panorâmica, zoom e personalize sua visualização
intervalo
barras
A granularidade da barra se adapta ao período selecionado — passe o mouse sobre o gráfico para ver a abertura/máxima/mínima/fechamento de uma barra.
Sobre Puma Biotechnology Inc - Common Stock Visão geral da empresa da Wikipedia
Puma Biotechnology is a publicly traded biopharmaceutical company (NASDAQ: PBYI) headquartered in Los Angeles, CA.
Creation
Puma was founded in September 2010 by Alan Auerbach to identify and in-license compounds that were already in clinical development. This was the same business plan Auerbach had followed at Cougar Biotechnology, which he founded in 2003, and through which he in-licensed abiraterone acetate from BTG plc. Cougar further developed abiraterone before the company was sold to Johnson & Johnson in 2009. Auerbach brought many Cougar employees with him after founding Puma in 2010.
Funding for development
In August 2011 Puma licensed two drug candidates from Pfizer: neratinib (PB272) and an analog (PB357) to serve as a backup candidate.
As part of an approximately $60 million financing round in October 2011, Puma entered into a reverse merger with the shell company Innovative Acquisitions Corp., formed in 2007. In April 2012 the company's stock began trading over the counter. In October 2012 the company raised around $138 million and its shares were listed on the New York Stock Exchange.
In 2016 Puma discovered that Robert Gadimian, senior director of regulatory affairs, had twice bought and sold stock based on his knowledge of unpublished clinical trial results; Puma quickly fired him after conducting an internal investigation and reported the insider trading to the SEC.
Approval and licensing of neratinib
In March 2016 Puma held a pre-NDA meeting with the FDA in which the FDA raised concerns about the design and conduct of clinical trials that Puma had run and recommended that Puma not file the NDA with that data.
Puma did file the NDA, and in May 2017 an FDA review panel recommended that the FDA approve neratinib but raised concerns that the intended use was too broad and should be limited to people with specific mutations. The FDA's briefing document to the panel had raised concerns about the marginal benefit of the drug and the side effects. In July 2017 the FDA approved neratinib for use in preventing the return of breast cancer after treatment that included trastuzumab and without any need for genetic testing, and with warnings about the risk of severe diarrhea. U.S. sales of neratinib totaled $200.5 million in 2018.
In January 2018 an EMA committee gave a negative review to neratinib. In June 2018 this same EMA committee recommended the approval of neratinib, which received European Commission (EC) approval in September 2018.
In 2019 Puma licensed commercialization rights in Europe and part of Africa to Pierre Fabre for an upfront payment of $60 million and milestone payments that could reach $345 million. Previously, Puma licensed rights in Greater China to CANbrdige Life Sciences, rights in Israel to Medison Pharma, rights in Canada to Knight Therapeutics, rights in South East Asian to Specialised Therapeutics and rights in Latin America to Pint Pharma.
== References ==
Fonte: Wikipedia (Inglês), CC BY-SA 4.0 · Ver na Wikipedia ↗
setorHealthcare
indústriaBiotechnology
funcionários179
paísUS
Desempenho de 10 Anos Tendências de receita, lucro líquido, margens e EPS
Receita$228M2017-12-31 → 2025-12-31
EPS$0.612020-12-31 → 2025-12-31
Fluxo de caixa livre$42M2016-12-31 → 2025-12-31
Margem líquida11.6%2017-12-31 → 2025-12-31
Avaliação e Proporções
Avaliação Rácios P/E, P/S, P/B, EV/EBITDA — a ação está cara ou barata?
| Métrica | Tendência de 5 anos | PBYI | média 5A | Mediana de Pares | Veredito |
|---|---|---|---|---|---|
| P/E (TTM) | 18.3média 5A ≈5.0 | ≈5.0 | · | · | |
| P/S (TTM) | 2.1média 5A ≈0.8 | ≈0.8 | 7.3 | Subvalorizado | |
| P/B (MRQ) | 3.5média 5A ≈-6.8 | ≈-6.8 | 3.0 | Valor justo | |
| EV / EBITDA | 11.0média 5A ≈26.1 | ≈26.1 | · | · | |
| Preço / FCF (TTM) | 11.8média 5A ≈2.7 | ≈2.7 | · | · | |
| Preço / Fluxo de Caixa (TTM) | 11.8média 5A ≈2.7 | ≈2.7 | · | · | |
| EV / Receita (TTM) | 1.7média 5A ≈0.8 | ≈0.8 | · | · | |
| EV / FCF (TTM) | 9.5média 5A ≈2.1 | ≈2.1 | · | · | |
| Price / Tangible Book (Preço / Valor Patrimonial Tangível) | 5.4 | · | · | · |
A mediana dos pares é calculada em uma base padronizada por métrica e pode não corresponder sempre à base TTM/MRQ mostrada para esta ação.
Lucratividade Margens bruta, operacional e líquida; ROE, ROA, ROIC
| Métrica | Tendência de 5 anos | PBYI | média 5A | Mediana de Pares | Veredito |
|---|---|---|---|---|---|
| Margem Operacional (TTM) | 13.2%média 5A ≈10.9% | ≈10.9% | -191.1% | Primeira linha | |
| EBITDA Margin (Margem EBITDA) | 16.3%média 5A ≈10.9% | ≈10.9% | -184.7% | Primeira linha | |
| Margem de Impostos Pré-Tributação (TTM) | 13.5%média 5A ≈4.9% | ≈4.9% | -113.8% | Primeira linha | |
| Margem de Lucro Líquido (TTM) | 11.6%média 5A ≈4.9% | ≈4.9% | -181.7% | Primeira linha | |
| ROA (TTM) | 13.8%média 5A ≈5.1% | ≈5.1% | -17.8% | Primeira linha | |
| ROE (TTM) | 22.0%média 5A ≈109.2% | ≈109.2% | -18.7% | Primeira linha | |
| ROIC | 21.2%média 5A ≈13.5% | ≈13.5% | -22.3% | Primeira linha |
Saúde financeira Dívida, liquidez, solvência — força do balanço patrimonial
| Métrica | Tendência de 5 anos | PBYI | média 5A | Mediana de Pares | Veredito |
|---|---|---|---|---|---|
| Dívida / Patrimônio Líquido (MRQ) | 0.0média 5A ≈-6.5 | ≈-6.5 | · | · | |
| Índice de liquidez corrente (MRQ) | 2.9média 5A ≈1.6 | ≈1.6 | 12.6 | Baixa liquidez | |
| Índice de Liquidez Seca (MRQ) | 2.6média 5A ≈1.5 | ≈1.5 | 2.9 | Baixa liquidez | |
| Dívida de Longo Prazo / Patrimônio Líquido (MRQ) | 0.0média 5A ≈-6.7 | ≈-6.7 | · | · |
Crescimento Crescimento da receita, EPS e lucro líquido: YoY, CAGR 3 anos, CAGR 5 anos
| Métrica | Tendência de 5 anos | PBYI | média 5A | Mediana de Pares | Veredito |
|---|---|---|---|---|---|
| Revenue YoY (Receita Ano a Ano) | -0.91%média 5A ≈0.56% | ≈0.56% | · | · | |
| Revenue CAGR 3Y (CAGR Receita 3A) | 0.05%média 5A ≈-0.50% | ≈-0.50% | · | · | |
| Revenue CAGR 5Y (CAGR Receita 5A) | 0.29% | · | · | · | |
| EPS YoY | -1.6% | · | · | · | |
| Net Income YoY (Lucro Líquido Ano a Ano) | 2.8%média 5A ≈359831.0% | ≈359831.0% | · | · | |
| Net Income CAGR 3Y (CAGR de Lucro Líquido 3A) | 2396.3% | · | · | · |
Eficiência de Capital Giro de ativos, giro de estoques, giro de contas a receber
| Métrica | Tendência de 5 anos | PBYI | média 5A | Mediana de Pares | Veredito |
|---|---|---|---|---|---|
| Asset Turnover (Giro do Ativo) | 1.1média 5A ≈1.0 | ≈1.0 | 0.1 | Primeira linha | |
| Inventory Turnover (Giro de Estoque) | 8.2média 5A ≈9.7 | ≈9.7 | · | · | |
| Receivables Turnover (Giro de Contas a Receber) | 5.3média 5A ≈6.3 | ≈6.3 | · | · | |
| Revenue / Employee (Receita anual ÷ funcionários (número de funcionários reportado, yfinance). Derivado — não é um conceito SEC-XBRL armazenado.) | ≈$1.3M | · | · | · |
valor · ≈ média 5A · mediana do setor · veredicto relativo à mediana
Histórico de Lucros EPS real vs. estimativa, surpresa %, taxa de acerto, próxima data de resultados
Surpresa Média
171.8%
Próximo relatório
Nov 04, 2026
| Período | Relatório | EPS Actual | EPS est. | Surpresa |
|---|---|---|---|---|
| 30 de Junho de 2026 | Ago 5, 2026 | $0.16 | $0.04 | 292.2% |
| 31 de Março de 2026 | $-0.07 | $-0.13 | 47.2% | |
| 31 de Dezembro de 2025 | $0.26 | $0.23 | 12.3% | |
| 30 de Setembro de 2025 | $0.17 | $0.05 | 270.4% | |
| 30 de Junho de 2025 | $0.12 | $0.10 | 14.6% | |
| 31 de Março de 2025 | $0.06 | $-0.02 | 394.1% |
Fundamentos Completos Todas as métricas por ano — demonstração de resultados, balanço patrimonial, fluxo de caixa
Demonstração de Resultados
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $228M | $230M | $236M | $228M | $253M | $225M | $272M | $251M | $28M | |
| Cost of Revenue | $58M | $64M | $63M | $55M | $64M | $39M | $37M | $35M | $6M | |
| R&D Expense | · | · | · | · | $72M | $98M | $133M | $165M | $208M | |
| SG&A Expense | $71M | $80M | $90M | $90M | $116M | $118M | $142M | $146M | $107M | |
| Operating Expenses | $191M | $200M | $203M | $204M | $252M | $256M | $311M | $346M | $320M | |
| Operating Income | $37M | $31M | $33M | $24M | $1M | $-30M | $-39M | $-95M | $-292M | |
| Interest Expense | · | · | $13M | $12M | $13M | $14M | $15M | $11M | $720.0K | |
| Interest Income | $4M | $5M | $3M | $813.0K | $160.0K | $489.0K | $3M | $2M | $1M | |
| Other Non-op | $1M | $862.0K | $759.0K | $-28.0K | $292.0K | $367.0K | $128.0K | $-714.0K | $-101.0K | |
| Pretax Income | $36M | $24M | $23M | $457.0K | $-29M | $-60M | $-76M | $-114M | · | |
| Income Tax | $5M | $-6M | $1M | $455.0K | $324.0K | $207.0K | $53.0K | $17.0K | $0 | |
| Net Income | $31M | $30M | $22M | $2.0K | $-29M | $-60M | $-76M | $-114M | $-292M | |
| EPS (Basic) | $0.62 | $0.62 | $0.46 | $0.00 | $-0.72 | $-1.52 | $-75595.00 | · | · | |
| EPS (Diluted) | $0.61 | $0.62 | $0.45 | $0.00 | $-0.72 | $-1.52 | · | · | · | |
| Shares (Basic) | 50,011,485 | 48,648,701 | 47,134,331 | 44,674,501 | 40,638,852 | 39,576,107 | · | · | · | |
| Shares (Diluted) | 50,653,283 | 49,100,433 | 47,550,852 | 44,929,998 | 40,638,852 | 39,576,107 | · | · | · | |
| EBITDA | $37M | $31M | $33M | $24M | $1M | $-30M | $-39M | $-95M | $-292M |
Balanço Patrimonial
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $30M | $69M | $85M | $76M | $63M | $85M | $60M | $108M | $82M | |
| Short-term Investments | $68M | $32M | $11M | $5M | $19M | $8M | $52M | $57M | · | |
| Receivables | $54M | $32M | $48M | $40M | $33M | $26M | $29M | $21M | $10M | |
| Inventory | $6M | $9M | $7M | $5M | $7M | $3M | $3M | $3M | $2M | |
| Prepaid Expense | $4M | $6M | $4M | $6M | $9M | $11M | $13M | $12M | $13M | |
| Other Current Assets | $256.0K | $91.0K | $912.0K | $2M | $447.0K | $4M | $323.0K | $2M | · | |
| Current Assets | $163M | $148M | $156M | $134M | $140M | $146M | $166M | $203M | $106M | |
| PP&E (Net) | $187.0K | $515.0K | $855.0K | $1M | $2M | $2M | $3M | $4M | $4M | |
| PP&E (Gross) | $5M | $8M | $9M | $9M | $9M | $9M | $9M | $9M | $9M | |
| Accum. Depreciation | $5M | $8M | $8M | $7M | $7M | $6M | $6M | $5M | $4M | |
| Intangibles | $41M | $51M | $61M | $71M | $66M | $74M | $40M | $44M | $48M | |
| Total Assets | $216M | $213M | $231M | $222M | $227M | $244M | $235M | $259M | $166M | |
| Accounts Payable | $5M | $6M | $7M | $6M | $11M | $12M | $19M | $21M | $28M | |
| Accrued Liabilities | $50M | $37M | $53M | $53M | $93M | $61M | $69M | $46M | $31M | |
| Current Liabilities | $81M | $96M | $99M | $77M | $110M | $114M | $91M | $67M | $58M | |
| Capital Leases | $5M | $1M | $7M | $12M | $16M | $20M | $23M | · | · | |
| Other Non-current Liabilities | $0 | $121.0K | $121.0K | · | · | · | · | · | · | |
| Total Liabilities | $86M | $121M | $177M | $200M | $229M | $250M | $217M | $225M | $112M | |
| Long-term Debt | $23M | $68M | $102M | $102M | $102M | $84M | $95M | $152M | $48M | |
| Total Debt | $23M | $67M | $100M | $98M | $97M | $98M | · | · | · | |
| Common Stock | $5.0K | $5.0K | $5.0K | $5.0K | $4.0K | $4.0K | $4.0K | $4.0K | $4.0K | |
| Retained Earnings | $-1.28B | $-1.31B | $-1.35B | $-1.37B | $-1.37B | $-1.34B | $-1.28B | $-1.20B | $-1.09B | |
| AOCI | $36.0K | $6.0K | $-4.0K | $0 | $-2.0K | $0 | $62.0K | $-12.0K | · | |
| Stockholders' Equity | $130M | $92M | $53M | $22M | $-2M | $-6M | $17M | $34M | $53M | |
| Liabilities + Equity | $216M | $213M | $231M | $222M | $227M | $244M | $235M | $259M | $166M | |
| Shares Outstanding | 50,408,023 | 49,105,834 | 47,646,787 | 46,345,660 | 41,175,507 | 40,086,387 | 39,203,304 | 38,325,037 | 37,594,851 |
Fluxo de Caixa
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $11M | $12M | $12M | $10M | $11M | $10M | $8M | $7M | $3M | |
| Stock-based Comp | $7M | $8M | $10M | $12M | $33M | $37M | $57M | $87M | $109M | |
| Deferred Tax | $3M | $-7M | $0 | $0 | · | · | · | · | · | |
| Amort. of Intangibles | $10M | $10M | $8M | $8M | $8M | $6M | $4M | $4M | $2M | |
| Operating Cash Flow | $42M | $39M | $27M | $-16M | $21M | $773.0K | $22M | $-24M | $-172M | |
| CapEx | $71.0K | $56.0K | $140.0K | $0 | $0 | $46.0K | $306.0K | $439.0K | $431.0K | |
| Investing Cash Flow | $-36M | $-20M | $-19M | $7M | $-11M | $33M | $5M | $-58M | $-15M | |
| Debt Issued | · | · | · | · | · | · | $25M | $105M | $50M | |
| Net Debt Issued | · | · | · | · | · | · | $25M | $105M | $50M | |
| Financing Cash Flow | $-45M | $-34M | $0 | $12M | $-32M | $-10M | $-67M | $108M | $75M | |
| Net Change in Cash | $-40M | $-15M | $8M | $4M | $-22M | $24M | $-40M | $27M | $-113M | |
| Taxes Paid | $1M | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $42M | $39M | $27M | $-16M | $21M | · | · | $-25M | $-173M | |
| Levered FCF | · | · | $14M | $-16M | $8M | · | · | · | · |
Lucratividade
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 16.3% | 13.4% | 13.9% | 10.4% | 0.51% | -13.5% | -14.4% | -37.7% | -1056.1% | |
| Net Margin | 13.6% | 13.1% | 9.2% | 0.00% | -11.5% | -26.7% | -27.8% | -45.2% | -1054.6% | |
| Pretax Margin | 15.7% | 10.5% | 9.6% | 0.20% | -11.4% | -26.6% | · | · | · | |
| EBITDA Margin | 16.3% | 13.4% | 13.9% | 10.4% | 0.51% | -13.5% | -14.4% | -37.7% | -1056.1% | |
| ROA | 14.5% | 13.6% | 9.5% | 0.00% | -12.4% | -25.0% | -30.6% | -53.5% | -139.6% | |
| ROE | 26.5% | 37.1% | 46.8% | 0.01% | 435.8% | 1873.7% | -436.4% | -283.2% | -221.9% | |
| ROIC | 21.2% | 24.4% | 20.3% | 0.09% | 1.4% | -33.0% | · | · | · |
Liquidez e Solvência
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.0 | 1.5 | 1.6 | 1.7 | 1.3 | 1.3 | 1.8 | 3.0 | 1.8 | |
| Quick Ratio | 1.9 | 1.4 | 1.4 | 1.6 | 1.0 | 1.0 | 1.5 | 2.8 | 1.6 | |
| Debt / Equity | 0.2 | 0.7 | 1.9 | 4.5 | -39.7 | -16.5 | · | · | · | |
| LT Debt / Equity | 0.0 | 0.2 | 1.2 | 4.5 | -39.7 | -14.1 | · | · | · | |
| Interest Coverage | · | · | 2.4 | 2.0 | 0.1 | -2.2 | -2.6 | -8.6 | -406.1 |
Eficiência
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 1.1 | 1.0 | 1.0 | 1.0 | 1.1 | 0.9 | 1.1 | 1.2 | 0.1 | |
| Inventory Turnover | 8.2 | 8.2 | 10.8 | 9.5 | 12.1 | · | · | 14.9 | 5.5 | |
| Receivables Turnover | 5.3 | 5.8 | 5.3 | 6.3 | 8.7 | 8.3 | 11.0 | 16.5 | 5.7 |
Por Ação
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $2.59 | $1.88 | $1.12 | $0.52 | $-0.06 | $-0.15 | $0.45 | $0.90 | $1.42 | |
| Revenue / Share | $4.51 | $4.69 | $4.96 | $5.08 | · | · | · | · | · | |
| Cash Flow / Share | $0.83 | $0.79 | $0.57 | $-0.35 | · | · | · | · | · | |
| Cash / Share | $0.59 | $1.41 | $1.78 | $1.85 | $1.57 | $2.13 | $1.53 | $2.83 | $2.17 | |
| EPS (TTM) | $0.61 | $0.62 | $0.45 | $0.00 | $-0.72 | $-1.52 | · | · | · |
Taxas de Crescimento
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | -0.91% | -2.2% | 3.3% | -9.9% | 12.5% | · | · | · | · | |
| Revenue CAGR 3Y | 0.05% | -3.1% | 1.5% | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 0.29% | · | · | · | · | · | · | · | · | |
| EPS YoY | -1.6% | 37.8% | · | · | · | · | · | · | · | |
| Net Income YoY | 2.8% | 40.2% | 1079450.0% | · | · | · | · | · | · | |
| Net Income CAGR 3Y | 2396.3% | · | · | · | · | · | · | · | · |
Avaliação (TTM)
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $228M | $230M | $236M | $228M | $253M | $225M | $272M | $251M | $28M | |
| Net Income TTM | $31M | $30M | $22M | $2.0K | $-29M | $-60M | $-76M | $-114M | $-292M | |
| Market Cap | $300M | $150M | $206M | $174M | $122M | $411M | $343M | $780M | $3.72B | |
| Enterprise Value | $225M | $116M | $210M | $191M | $137M | $416M | · | · | · | |
| P/E | 9.8 | 4.9 | 9.6 | · | -4.2 | -6.8 | · | · | · | |
| P/S | 1.3 | 0.6 | 0.9 | 0.8 | 0.5 | 1.8 | 1.3 | 3.1 | 134.2 | |
| P/B | 2.3 | 1.6 | 3.9 | 8.1 | -49.8 | -69.1 | 19.6 | 22.7 | 69.7 | |
| P / Tangible Book | 3.4 | 3.7 | · | · | · | · | · | · | · | |
| P / Cash Flow | 7.2 | 3.8 | 7.6 | -11.0 | 5.9 | 532.1 | 15.3 | -32.4 | -21.5 | |
| P / FCF | 7.2 | 3.9 | 7.7 | -11.0 | 5.9 | · | · | -31.8 | -21.5 | |
| EV / EBITDA | 6.0 | 3.7 | 6.4 | 8.1 | 106.1 | -13.7 | · | · | · | |
| EV / FCF | 5.4 | 3.0 | 7.8 | -12.1 | 6.6 | · | · | · | · | |
| EV / Revenue | 1.0 | 0.5 | 0.9 | 0.8 | 0.5 | 1.8 | · | · | · | |
| Earnings Yield | 10.2% | 20.3% | 10.4% | 0.00% | -23.7% | -14.8% | · | · | · |
Demonstração de Resultados
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $57M | $45M | $75M | $54M | $52M | $46M | $59M | $81M | $47M | $44M | $72M | $56M | $55M | $53M | $66M | $57M | |
| Cost of Revenue | $12M | $10M | $23M | $12M | $12M | $11M | $14M | $29M | $11M | $11M | $24M | $13M | $12M | $13M | $17M | $12M | |
| SG&A Expense | $18M | $18M | $18M | $17M | $18M | $18M | $17M | $17M | $25M | $22M | $20M | $23M | $24M | $22M | $25M | $24M | |
| Operating Expenses | $49M | $49M | $58M | $45M | $46M | $42M | $46M | $58M | $49M | $46M | $57M | $48M | $50M | $48M | $56M | $55M | |
| Operating Income | $8M | $-4M | $17M | $10M | $7M | $4M | $13M | $22M | $-2M | $-2M | $15M | $9M | $5M | $4M | $10M | $2M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $3M | · | $3M | $3M | $3M | · | $3M | |
| Interest Income | $831.0K | $1M | $977.0K | $1M | $956.0K | $1M | $1M | $1M | $1M | $972.0K | $719.0K | $689.0K | $660.0K | $537.0K | $519.0K | $216.0K | |
| Other Non-op | $9.0K | $130.0K | $143.0K | $115.0K | $410.0K | $359.0K | $268.0K | $347.0K | $156.0K | $91.0K | $641.0K | $74.0K | $86.0K | $-42.0K | $-204.0K | $64.0K | |
| Pretax Income | $8M | $-3M | $17M | $9M | $6M | $3M | $12M | $21M | $-4M | $-5M | $13M | $6M | $2M | $2M | $-5M | $-293.0K | |
| Income Tax | · | · | · | · | · | · | $-7M | $291.0K | $378.0K | $220.0K | $536.0K | $213.0K | $187.0K | $147.0K | $294.0K | $67.0K | |
| Net Income | $8M | $-4M | $13M | $9M | $6M | $3M | $19M | $20M | $-5M | $-5M | $12M | $6M | $2M | $1M | $-6M | $-360.0K | |
| EPS (Basic) | $0.16 | $-0.07 | $0.26 | $0.18 | $0.12 | $0.06 | $0.40 | $0.41 | $-0.09 | $-0.10 | $0.26 | $0.12 | $0.05 | $0.03 | $-0.12 | $-0.01 | |
| EPS (Diluted) | $0.16 | $-0.07 | $0.26 | $0.17 | $0.12 | $0.06 | $0.40 | $0.41 | $-0.09 | $-0.10 | $0.25 | $0.12 | $0.05 | $0.03 | $-0.12 | $-0.01 | |
| Shares (Basic) | 50,939,946 | 50,845,130 | · | 50,339,456 | 49,700,217 | 49,595,697 | · | 49,008,464 | 48,292,414 | 48,189,256 | · | 47,520,338 | 46,759,062 | 46,636,083 | · | 45,567,739 | |
| Shares (Diluted) | 52,596,589 | 50,845,130 | · | 50,929,893 | 50,144,704 | 49,906,341 | · | 49,173,361 | 48,292,414 | 48,189,256 | · | 47,819,234 | 47,201,185 | 47,157,904 | · | 45,567,739 | |
| EBITDA | $8M | $-4M | · | $10M | $7M | · | · | $22M | $-2M | $-2M | · | $9M | $5M | $4M | · | $2M |
Balanço Patrimonial
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $37M | $36M | $30M | $54M | $55M | $63M | $69M | $67M | $67M | $77M | · | $82M | $60M | $61M | · | $78M | |
| Short-term Investments | $57M | $65M | $68M | $41M | $41M | $30M | $32M | $29M | $30M | $30M | · | $3M | $14M | $10M | · | $0 | |
| Receivables | $34M | $26M | $54M | $34M | $26M | $25M | $32M | $55M | $28M | $25M | · | $29M | $31M | $31M | · | $28M | |
| Inventory | $13M | $9M | $6M | $9M | $9M | $9M | $9M | $3M | $9M | $7M | · | $6M | $8M | $4M | · | $5M | |
| Prepaid Expense | $4M | $3M | $4M | $4M | $4M | $5M | $6M | $3M | $3M | $4M | · | $4M | $5M | $5M | · | $7M | |
| Other Current Assets | $199.0K | $196.0K | $256.0K | $230.0K | $73.0K | $98.0K | $91.0K | $236.0K | $241.0K | $255.0K | · | $2M | $573.0K | $449.0K | · | $4M | |
| Current Assets | $145M | $142M | $163M | $144M | $137M | $133M | $148M | $157M | $138M | $143M | · | $125M | $119M | $112M | · | $122M | |
| PP&E (Net) | $103.0K | $124.0K | $187.0K | $305.0K | $388.0K | $474.0K | $515.0K | $601.0K | $680.0K | $757.0K | · | $907.0K | $977.0K | $1M | · | $1M | |
| PP&E (Gross) | $3M | $3M | $5M | $7M | $8M | $8M | $8M | $9M | $9M | $9M | · | $9M | $9M | $9M | · | $9M | |
| Accum. Depreciation | $3M | $3M | $5M | $7M | $8M | $8M | $8M | $8M | $8M | $8M | · | $8M | $8M | $8M | · | $7M | |
| Intangibles | · | · | $41M | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Total Assets | $193M | $193M | $216M | $203M | $195M | $196M | $213M | $221M | $205M | $214M | · | $204M | $200M | $196M | · | $199M | |
| Accounts Payable | $3M | $8M | $5M | $6M | $5M | $6M | $6M | $8M | $14M | $9M | · | $5M | $8M | $9M | · | $15M | |
| Accrued Liabilities | $45M | $38M | $50M | $37M | $32M | $27M | $37M | $51M | $39M | $38M | · | $34M | $35M | $34M | · | $40M | |
| Current Liabilities | $50M | $60M | $81M | $83M | $79M | $87M | $96M | $110M | $104M | $98M | · | $67M | $60M | $48M | · | $60M | |
| Capital Leases | $4M | $5M | $5M | $5M | $0 | $0 | $1M | $3M | $4M | $6M | · | $8M | $10M | $11M | · | $13M | |
| Other Non-current Liabilities | · | · | $0 | $0 | $0 | $0 | $121.0K | $121.0K | $121.0K | · | · | · | · | · | · | · | |
| Total Liabilities | $54M | $64M | $86M | $88M | $90M | $99M | $121M | $150M | $156M | $163M | · | $165M | $170M | $170M | · | $177M | |
| Long-term Debt | $0 | $11M | $23M | $34M | $45M | $57M | $67M | $79M | $91M | $102M | · | $102M | $102M | $102M | · | $102M | |
| Total Debt | $0 | $11M | · | $34M | $45M | · | · | $78M | $89M | $100M | · | $99M | $99M | $99M | · | $98M | |
| Common Stock | $5.0K | $5.0K | $5.0K | $5.0K | $5.0K | $5.0K | $5.0K | $5.0K | $5.0K | $5.0K | · | $5.0K | $5.0K | $5.0K | · | $5.0K | |
| Retained Earnings | $-1.28B | $-1.29B | $-1.28B | $-1.30B | $-1.31B | $-1.31B | $-1.31B | $-1.33B | $-1.35B | $-1.35B | · | $-1.36B | $-1.36B | $-1.37B | · | $-1.36B | |
| AOCI | $-45.0K | $-31.0K | $36.0K | $19.0K | $-14.0K | $-11.0K | $6.0K | $26.0K | $-32.0K | $-26.0K | · | $-4.0K | $-6.0K | · | · | $0 | |
| Stockholders' Equity | $139M | $128M | $130M | $115M | $105M | $97M | $92M | $71M | $49M | $51M | $53M | $39M | $30M | $26M | $22M | $22M | |
| Liabilities + Equity | $193M | $193M | $216M | $203M | $195M | $196M | $213M | $221M | $205M | $214M | · | $204M | $200M | $196M | · | $199M | |
| Shares Outstanding | 51,102,687 | 50,879,204 | 50,408,023 | 50,384,274 | 49,892,725 | 49,615,174 | 49,105,834 | 49,067,348 | 48,460,120 | 48,214,663 | 47,646,787 | 47,542,790 | 46,947,153 | 46,663,599 | 46,345,660 | 45,608,814 |
Fluxo de Caixa
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $2M | $3M | |
| Stock-based Comp | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $3M | $2M | $3M | $3M | $3M | |
| Amort. of Intangibles | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $800.0K | $2M | $2M | $2M | $2M | $2M | |
| Operating Cash Flow | $2M | $15M | $14M | $10M | $14M | $4M | $16M | $11M | $1M | $11M | $10M | $11M | $3M | $3M | $8M | $17M | |
| CapEx | $0 | $0 | $-36.0K | $26.0K | $20.0K | $61.0K | $16.0K | $20.0K | $20.0K | $0 | $45.0K | $27.0K | · | · | $0 | $0 | |
| Investing Cash Flow | $8M | $2M | $-27M | $506.0K | $-11M | $2M | $-2M | $259.0K | $703.0K | $-19M | $-8M | $11M | $-5M | $-17M | $-12M | $8M | |
| Financing Cash Flow | $-11M | $-11M | $-11M | $-11M | $-11M | $-11M | $-11M | $-11M | $-11M | $0 | $0 | $0 | $0 | $0 | $2M | $-53.0K | |
| Net Change in Cash | $-2M | $7M | $-24M | $-1M | $-8M | $-6M | $2M | $114.0K | $-10M | $-8M | $2M | $22M | $-1M | $-15M | $-2M | $25M | |
| Free Cash Flow | · | $15M | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
Lucratividade
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 13.4% | -8.5% | · | 17.6% | 12.7% | · | · | 27.4% | -4.6% | -5.2% | · | 15.3% | 9.0% | 8.3% | · | 4.2% | |
| Net Margin | 14.5% | -8.4% | · | 16.2% | 11.2% | · | · | 25.2% | -9.6% | -11.0% | · | 10.3% | 3.9% | 2.6% | · | -0.63% | |
| Pretax Margin | 14.6% | -7.6% | · | 17.0% | 11.8% | · | · | 25.6% | -8.8% | -10.5% | · | 10.7% | 4.2% | 2.9% | · | -0.51% | |
| EBITDA Margin | 13.4% | -8.5% | · | 17.6% | 12.7% | · | · | 27.4% | -4.6% | -5.2% | · | 15.3% | 9.0% | 8.3% | · | 4.2% | |
| ROA | 4.2% | -1.9% | · | 4.2% | 2.9% | · | · | 9.6% | -2.2% | -2.4% | · | 2.9% | 1.1% | 0.71% | · | -0.17% | |
| ROE | 6.7% | -3.3% | · | 9.5% | 7.6% | · | · | 37.0% | -11.5% | -12.5% | · | 19.0% | 8.5% | 8.5% | · | -6.4% | |
| ROIC | · | · | · | · | · | · | · | 14.6% | -1.7% | -1.6% | · | 6.0% | 3.5% | 3.2% | · | 2.5% |
Liquidez e Solvência
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.9 | 2.4 | · | 1.7 | 1.7 | · | · | 1.4 | 1.3 | 1.5 | · | 1.9 | 2.0 | 2.3 | · | 2.0 | |
| Quick Ratio | 2.6 | 2.1 | · | 1.5 | 1.5 | · | · | 1.4 | 1.2 | 1.3 | · | 1.7 | 1.8 | 2.1 | · | 1.8 | |
| Debt / Equity | 0.0 | 0.1 | · | 0.3 | 0.4 | · | · | 1.1 | 1.8 | 2.0 | · | 2.6 | 3.3 | 3.8 | · | 4.4 | |
| LT Debt / Equity | 0.0 | 0.0 | · | 0.0 | 0.1 | · | · | 0.5 | 0.9 | 1.1 | · | 2.0 | 2.9 | 3.8 | · | 4.4 | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | -0.7 | · | 2.6 | 1.5 | 1.3 | · | 0.8 |
Eficiência
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.3 | 0.2 | · | 0.3 | 0.3 | · | · | 0.4 | 0.2 | 0.2 | · | 0.3 | 0.3 | 0.3 | · | 0.3 | |
| Inventory Turnover | 1.1 | 1.2 | · | 2.0 | 1.4 | · | · | 7.0 | 1.3 | 2.0 | · | 2.4 | 1.7 | 2.4 | · | 2.0 | |
| Receivables Turnover | 1.9 | 1.7 | · | 1.2 | 1.9 | · | · | 1.9 | 1.6 | 1.6 | · | 2.0 | 1.7 | 1.8 | · | 2.2 |
Por Ação
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $2.71 | $2.52 | · | $2.29 | $2.10 | · | · | $1.45 | $1.00 | $1.06 | · | $0.81 | $0.65 | $0.55 | · | $0.49 | |
| Revenue / Share | $1.07 | $0.88 | · | $1.07 | $1.05 | · | · | $1.64 | $0.97 | $0.91 | · | $1.17 | $1.16 | $1.12 | · | $1.25 | |
| Cash Flow / Share | · | $0.30 | · | · | · | · | · | · | · | $0.23 | · | · | · | $0.06 | · | · | |
| Cash / Share | $0.71 | $0.71 | · | $1.06 | $1.10 | · | · | $1.37 | $1.39 | $1.59 | · | $1.72 | $1.28 | $1.32 | · | $1.71 | |
| EPS (TTM) | $0.52 | $0.48 | · | $0.75 | $0.99 | $0.28 | · | $0.47 | $0.18 | $0.32 | · | $0.08 | $-0.05 | $0.11 | · | $0.22 |
Avaliação (TTM)
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $231M | $227M | · | $212M | $238M | $217M | · | $244M | $219M | $227M | · | $229M | $230M | $235M | · | $218M | |
| Net Income TTM | $27M | $24M | · | $37M | $48M | $14M | · | $23M | $9M | $15M | · | $4M | $-2M | $5M | · | $10M | |
| Market Cap | $414M | $325M | · | $268M | $171M | · | · | $125M | $158M | $256M | · | $125M | $166M | $144M | · | $108M | |
| Enterprise Value | $321M | $235M | · | $207M | $120M | · | · | $106M | $150M | $248M | · | $139M | $190M | $172M | · | $128M | |
| P/E | 15.6 | 13.3 | · | 7.1 | 3.5 | 10.6 | · | 5.4 | 18.1 | 16.6 | · | 32.9 | -70.6 | 28.1 | · | 10.8 | |
| P/S | 1.8 | 1.4 | · | 1.3 | 0.7 | · | · | 0.5 | 0.7 | 1.1 | · | 0.5 | 0.7 | 0.6 | · | 0.5 | |
| P/B | 3.0 | 2.5 | · | 2.3 | 1.6 | · | · | 1.8 | 3.3 | 5.0 | · | 3.2 | 5.5 | 5.6 | · | 4.9 | |
| P / Tangible Book | 3.0 | 2.5 | · | 2.3 | 1.6 | 1.5 | · | 1.8 | 3.3 | 5.0 | · | 3.2 | 5.5 | 5.6 | · | 4.9 | |
| P / Cash Flow | · | 21.1 | · | · | · | · | · | · | · | 22.7 | · | · | · | 54.6 | · | · | |
| EV / Revenue | 1.4 | 1.0 | · | 1.0 | 0.5 | · | · | 0.4 | 0.7 | 1.1 | · | 0.6 | 0.8 | 0.7 | · | 0.6 | |
| Earnings Yield | 6.4% | 7.5% | · | 14.1% | 28.9% | 9.5% | · | 18.4% | 5.5% | 6.0% | · | 3.0% | -1.4% | 3.6% | · | 9.3% |
Período mais recente à esquerda · valores nulos mostrados como ·
Demonstrações Financeiras Demonstração de resultados, balanço patrimonial, fluxo de caixa — anual, últimos 5 anos
| Métrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Receita | $228M | $230M | $236M | $228M | $253M |
| Margem Operacional % | 16.3% | 13.4% | 13.9% | 10.4% | 0.51% |
| Lucro líquido | $31M | $30M | $22M | $2.0K | $-29M |
| EPS Diluído | $0.61 | $0.62 | $0.45 | $0.00 | $-0.72 |
| Métrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Dívida / Patrimônio Líquido | 0.2 | 0.7 | 1.9 | 4.5 | -39.7 |
| Índice de liquidez corrente | 2.0 | 1.5 | 1.6 | 1.7 | 1.3 |
| Índice de Liquidez Seca | 1.9 | 1.4 | 1.4 | 1.6 | 1.0 |
| Métrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Fluxo de caixa livre | $42M | $39M | $27M | $-16M | $21M |
Investidores institucionais (13F) 172 declarantes · $307.7M total · Em 30 de Setembro de 2026
Instituições que relatam a posse desta ação em seu Formulário 13F trimestral da SEC. Apenas posições compradas; um único declarante pode aparecer duas vezes para opções separadas. Grandes posições de compra/venda compensatórias geralmente refletem market-making ou inventário protegido, não convicção direcional.
Detentores
172
Valor detido
$307.7M
Novas posições
22
Posições encerradas
15
Atividade institucional — Q2 2026 vs trimestre anterior
| Novas posições | Posições encerradas | Aumentou | Diminuído | Variação líquida de ações |
|---|---|---|---|---|
| 22 (-8 vs trimestre anterior) | 15 (-1 vs trimestre anterior) | 60 (-1 vs trimestre anterior) | 53 (+16 vs trimestre anterior) | +896K |
Comparado a Q1 2026. Os registros do Formulário 13F da SEC devem ser feitos em até 45 dias após o final do trimestre, mais um pequeno período de tolerância para registrantes atrasados — trimestres ainda dentro desse período são ignorados em favor do par mais recente totalmente reportado.
| Instituição | Valor | Ações | % de 13F rastreado | Tipo |
|---|---|---|---|---|
| ACORN CAPITAL ADVISORS, LLC | $33.504.835 | 4.131.299 | 10,89% | Ações |
| BlackRock, Inc. | $30.856.410 | 3.804.736 | 10,03% | Ações |
| VANGUARD GROUP INC | $22.596.600 | 3.797.748 | 7,34% | Ações |
| AMERICAN CENTURY COMPANIES INC | $18.815.168 | 2.319.996 | 6,11% | Ações |
| RENAISSANCE TECHNOLOGIES LLC | $14.891.687 | 1.836.213 | 4,84% | Ações |
| VANGUARD CAPITAL MANAGEMENT LLC | $14.887.065 | 1.835.643 | 4,84% | Ações |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $14.805.608 | 1.825.599 | 4,81% | Ações |
| DIMENSIONAL FUND ADVISORS LP | $12.311.629 | 1.518.014 | 4,00% | Ações |
| GEODE CAPITAL MANAGEMENT, LLC | $10.864.667 | 1.339.405 | 3,53% | Ações |
| O'SHAUGHNESSY ASSET MANAGEMENT, LLC | $9.113.880 | 1.123.783 | 2,96% | Ações |
| STATE STREET CORP | $7.722.058 | 952.165 | 2,51% | Ações |
| KENNEDY CAPITAL MANAGEMENT LLC | $7.082.082 | 873.253 | 2,30% | Ações |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | $6.420.006 | 791.616 | 2,09% | Ações |
| RITHOLTZ WEALTH MANAGEMENT | $6.080.862 | 749.798 | 1,98% | Ações |
| AQR CAPITAL MANAGEMENT LLC | $5.881.307 | 725.192 | 1,91% | Ações |
| GOLDMAN SACHS GROUP INC | $5.426.855 | 669.156 | 1,76% | Ações |
| NORTHERN TRUST CORP | $5.290.851 | 652.386 | 1,72% | Ações |
| Connor, Clark & Lunn Investment Management Ltd. | $5.214.292 | 642.946 | 1,69% | Ações |
| UBS Group AG | $5.164.131 | 636.761 | 1,68% | Ações |
| MILLENNIUM MANAGEMENT LLC | $4.884.166 | 602.240 | 1,59% | Ações |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $4.318.170 | 532.450 | 1,40% | Ações |
| SEI INVESTMENTS CO | $3.395.406 | 418.669 | 1,10% | Ações |
| GLOBEFLEX CAPITAL L P | $3.104.565 | 382.807 | 1,01% | Ações |
| Bank of New York Mellon Corp | $2.925.553 | 360.734 | 0,95% | Ações |
| D. E. Shaw & Co., Inc. | $2.565.542 | 316.343 | 0,83% | Ações |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $2.506.850 | 309.106 | 0,81% | Ações |
| Invesco Ltd. | $2.441.127 | 301.002 | 0,79% | Ações |
| Russell Investments Group, Ltd. | $2.207.818 | 272.234 | 0,72% | Ações |
| VANGUARD FIDUCIARY TRUST CO | $2.182.158 | 269.070 | 0,71% | Ações |
| MORGAN STANLEY | $2.154.584 | 265.670 | 0,70% | Ações |
| FEDERATED HERMES, INC. | $2.033.712 | 250.766 | 0,66% | Ações |
| Empowered Funds, LLC | $1.786.763 | 220.316 | 0,58% | Ações |
| PANAGORA ASSET MANAGEMENT INC | $1.764.290 | 217.545 | 0,57% | Ações |
| PRUDENTIAL FINANCIAL INC | $1.732.288 | 213.599 | 0,56% | Ações |
| JPMORGAN CHASE & CO | $1.730.866 | 211.339 | 0,56% | Ações |
| FMR LLC | $1.714.811 | 211.444 | 0,56% | Ações |
| STATE OF WISCONSIN INVESTMENT BOARD | $1.526.562 | 188.232 | 0,50% | Ações |
| FRANKLIN RESOURCES INC | $1.395.001 | 172.010 | 0,45% | Ações |
| Prospera Financial Services Inc | $1.287.530 | 158.762 | 0,42% | Ações |
| Haven Private, LLC | $1.203.913 | 148.448 | 0,39% | Ações |
| TWO SIGMA INVESTMENTS, LP | $1.140.161 | 140.587 | 0,37% | Ações |
| FIRST TRUST ADVISORS LP | $1.055.970 | 130.206 | 0,34% | Ações |
| Round Rock Advisors LLC | $1.045.476 | 128.912 | 0,34% | Ações |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $1.040.051 | 128.243 | 0,34% | Ações |
| WELLINGTON MANAGEMENT GROUP LLP | $1.022.598 | 126.091 | 0,33% | Ações |
| STRS OHIO | $686.106 | 84.600 | 0,22% | Ações |
| Nuveen, LLC | $667.437 | 82.298 | 0,22% | Ações |
| EVERGREEN CAPITAL MANAGEMENT LLC | $597.960 | 73.731 | 0,19% | Ações |
| CANADA PENSION PLAN INVESTMENT BOARD | $596.085 | 73.500 | 0,19% | Ações |
| Trexquant Investment LP | $585.729 | 72.223 | 0,19% | Ações |
Ativistas e proprietários de 5%+ 7 participações
Investidores que apresentaram o Schedule 13D da SEC — propriedade benéfica acima de 5% com a intenção de influenciar o emissor (participações ativistas, campanhas no conselho, M&A). Cada linha mostra o estado mais recente conhecido da posição desse declarante.
| Declarante | Declarado | Participação | Status | Propósito | Declaração |
|---|---|---|---|---|---|
| Alan H. Auerbach ×6 declarações | 13 de Dezembro de 2022 | · | Declaração inicial | Investimento passivo | SEC |
| Kapil Munjal 2) | 4 de Outubro de 2011 | · | Declaração inicial | · | SEC |
| Faraaz Siddiqi 2) | 4 de Outubro de 2011 | · | Declaração inicial | · | SEC |
| Robert Johnson 2) | 4 de Outubro de 2011 | · | Declaração inicial | · | SEC |
| Robert Johnson | 21 de Novembro de 2007 | · | Declaração inicial | · | SEC |
| Pessoa de relato não divulgada | 19 de Novembro de 2007 | · | Declaração inicial | · | SEC |
| Faraaz Siddiqi | 19 de Novembro de 2007 | · | Declaração inicial | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Executivos da empresa 24 insiders · 10 diretores · 12 conselheiros
| Investidor com informação privilegiada | Função | Última atividade | Ações detidas | Compras 12m | Vendas 12m | Líquido 12m |
|---|---|---|---|---|---|---|
| Alan H Auerbach | President and CEO | 6 de Julho de 2026 S | 7.261.671 | 0 | 3 | $-568.748 |
| Maximo F Nougues | Chief Financial Officer | 6 de Julho de 2026 S | 230.637 | 0 | 3 | $-141.703 |
| Douglas M Hunt | The Reporting Person is the Senior Vice President of Regulatory Affairs of the Issuer. | 6 de Julho de 2026 S | 196.841 | 0 | 3 | $-122.564 |
| Jeffrey Jerome Ludwig | Chief Commercial Officer | 7 de Fevereiro de 2025 A | 156.792 | 0 | 0 | $0 |
| Alvin F Wong | Chief Scientific Officer | 12 de Fevereiro de 2024 A | 141.241 | 0 | 0 | $0 |
| Richard Paul Bryce | Title of Reporting Person: Chief Medical and Scientific Officer | 5 de Abril de 2021 S | 121.662 | 0 | 0 | $0 |
| Steven Lo | Chief Commercial Officer | 22 de Julho de 2019 S | 19.557 | 0 | 0 | $0 |
| Charles R Eyler | Title of Reporting Person: Senior Vice President, Finance and Administration and Treasurer | 4 de Fevereiro de 2019 S | 31.957 | 0 | 0 | $0 |
| Robert Charnas | The Reporting Person is the Senior Vice President of Regulatory Affairs and Project Management of the Issuer. | 16 de Fevereiro de 2017 A | 26.453 | 0 | 0 | $0 |
| Richard Benton Phillips | The Reporting Person is the Interim Head of Regulatory Affairs, Quality Assurance and Pharmacovigilance of the Issuer. | 15 de Abril de 2016 A | · | 0 | 0 | $0 |
| Alessandra Cesano | Conselheiro | 14 de Setembro de 2026 M | 56.700 | 0 | 1 | $-566.808 |
| Troy Edward Wilson | Conselheiro | 14 de Setembro de 2026 S | 54.750 | 0 | 2 | $-123.260 |
| Brian M Stuglik | Conselheiro | 12 de Junho de 2026 S | 113.858 | 0 | 1 | $-58.320 |
| Allison Dorval | Conselheiro | 12 de Junho de 2026 S | 90.780 | 0 | 1 | $-83.592 |
| Adrian Senderowicz | Conselheiro | 12 de Junho de 2026 S | 27.000 | 0 | 1 | $-194.400 |
| Jay M Moyes | Conselheiro | 12 de Junho de 2026 S | 58.322 | 0 | 1 | $-158.840 |
| MILLER MICHAEL PATRICK | Conselheiro | 11 de Junho de 2026 A | 81.000 | 0 | 1 | $-97.200 |
| Ann Calby Miller | Conselheiro | 15 de Junho de 2021 A | 40.732 | 0 | 0 | $0 |
| Hugh O'Dowd | Conselheiro | 9 de Junho de 2020 A | 25.748 | 0 | 0 | $0 |
| Frank Zavrl | Conselheiro | 9 de Junho de 2020 A | 50.993 | 0 | 0 | $0 |
| Thomas Malley | Conselheiro | 15 de Dezembro de 2014 A | 156.551 | 0 | 0 | $0 |
| Faraaz Siddiqi | · | 4 de Outubro de 2011 D | 0 | 0 | 0 | $0 |
| Kapil Munjal | · | 4 de Outubro de 2011 D | 0 | 0 | 0 | $0 |
| Robert Andrew Johnson | · | 4 de Outubro de 2011 D | 0 | 0 | 0 | $0 |
Executivos de declarações SEC Formulário 3/4/5; líquido = apenas P/V de mercado aberto
Participação em ETFs Detido por 25 ETFs
O peso reflete apenas participações diretas em ações (N-PORT); fundos alavancados ou baseados em derivativos podem deter exposição adicional a swaps não mostrada.
| Fundo | Peso | Unidades | Em | Fonte |
|---|---|---|---|---|
| ROSC · Lattice Strategies Trust | 0,71% | 55.155 NS | 31 de Julho de 2026 | N-PORT |
| DWAS · Invesco Exchange-Traded Fund Trust … | 0,56% | 231.071 SH | 1 de Outubro de 2026 | Diário |
| IWC · iShares Trust | 0,10% | 149.805 SH | 11 de Setembro de 2026 | Diário |
| VFQY · VANGUARD WELLINGTON FUND | 0,06% | 34.260 SH | 19 de Agosto de 2026 | Diário |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,03% | 3.640 SH | 1 de Outubro de 2026 | Diário |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,02% | 55.175 SH | 1 de Outubro de 2026 | Diário |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,02% | 32.358 SH | 19 de Agosto de 2026 | Diário |
| IWM · iShares Trust | 0,01% | 1.181.450 SH | 11 de Setembro de 2026 | Diário |
| RSSL · Global X Funds | 0,01% | 21.135 NS | 31 de Julho de 2026 | N-PORT |
| VFMO · VANGUARD WELLINGTON FUND | 0,01% | 16.014 SH | 19 de Agosto de 2026 | Diário |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,01% | 254.380 SH | 19 de Agosto de 2026 | Diário |
| DFAT · Dimensional ETF Trust | 0,01% | 172.951 NS | 31 de Julho de 2026 | N-PORT |
| DFAS · Dimensional ETF Trust | 0,01% | 170.404 NS | 31 de Julho de 2026 | N-PORT |
| DFSV · Dimensional ETF Trust | 0,01% | 81.441 NS | 31 de Julho de 2026 | N-PORT |
| DXUV · Dimensional ETF Trust | 0,01% | 3.611 NS | 31 de Julho de 2026 | N-PORT |
| IWO · iShares Trust | 0,00% | 67.004 SH | 11 de Setembro de 2026 | Diário |
| DCOR · Dimensional ETF Trust | 0,00% | 6.348 NS | 31 de Julho de 2026 | N-PORT |
| DFAU · Dimensional ETF Trust | 0,00% | 12.537 NS | 31 de Julho de 2026 | N-PORT |
| DFUS · Dimensional ETF Trust | 0,00% | 15.090 NS | 31 de Julho de 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0,00% | 12.376 NS | 31 de Julho de 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0,00% | 446.899 SH | 19 de Agosto de 2026 | Diário |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 1.343.121 SH | 19 de Agosto de 2026 | Diário |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,00% | 7.680 SH | 19 de Agosto de 2026 | Diário |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 2.979 SH | 19 de Agosto de 2026 | Diário |
| IWN · iShares Trust | · | 357.993 SH | 11 de Setembro de 2026 | Diário |
PBYI Consenso dos analistas Opiniões de analistas otimistas e pessimistas, preço-alvo de 12 meses, potencial de alta
classificação · 6 analistas
VENDA
Alvo mediano
$6.00
-36,9%
0 0,0%
Compra forte
0 0,0%
Compra
3 50,0%
Manter
1 16,7%
Venda
2 33,3%
Venda forte
Preço-alvo de 12 meses
1 analistas · 2026-08-18Alvo médio $6.00 -36,9%
Mín$6.00
Média$6.00
Máx$6.00
Comparação de pares (subindústria GICS) Métricas chave vs pares do setor
Base do ano fiscal, preços no fechamento do último ano fiscal de cada empresa.
| Ticker | Capitalização de Mercado | P/E | Receita YoY | Margem Líquida | ROE | Margem Bruta |
|---|---|---|---|---|---|---|
| PBYI | $300M | 9.8 | -0.91% | 13.6% | 26.5% | · |
| ALLO | $314M | -1.6 | -76.8% | · | -59.9% | · |
| PROK | · | · | 1075.0% | -7725.2% | 6.9% | · |
| MNPR | · | · | · | · | · | · |
| CAPR | $1.66B | -12.8 | -11.6% | · | -51.1% | · |
| NGNE | $319M | -4.9 | · | · | -33.6% | · |
| RGNX | $733M | -3.8 | 104.5% | -113.8% | -122.5% | · |
| OVID | $212M | -4.0 | 1181.3% | -240.1% | -18.7% | · |
| ASMB | $539M | -61.8 | 153.5% | -8.5% | -5.5% | · |
| TECX | $391M | -5.2 | · | · | -27.7% | · |
| DMAC | $428M | · | · | · | -78.7% | · |
Minhas Métricas Sua lista pessoal — linhas selecionadas de Fundamentos Completos
Escolha as métricas que importam para si — clique no + ao lado de qualquer linha em Fundamentos Completos acima.
Sua seleção é salva e acompanha você em todos os tickers.
Fonte: SEC 10-Q arquivado Ago 6, 2026